The British Journal of Psychiatry 174: 297-303 (1999)
© 1999 The Royal College of Psychiatrists

Effectiveness of antidepressants. Meta-analysis of dose-effect relationships in randomised clinical trials

P Bollini, S Pampallona, G Tibaldi, B Kupelnick and C Munizza
Centro Studi e Ricerche in Psichiatria, Turin, Italy.

BACKGROUND: Antidepressant drugs are usually prescribed at low doses, possibly to avoid adverse reactions. No comprehensive review has addressed the issue of dose, clinical response and tolerability in a quantitative way. AIMS: To determine whether high doses of antidepressants are more effective than low doses, and how safety is affected by dose. METHOD: Trials comparing two or more doses of the same antidepressant were located, and all antidepressants administered were converted to the equivalent dose of imipramine. Generalised estimating equations were used to analyse percentage improvement and adverse event rate according to dose level. RESULTS: Thirty-three studies were identified. The dose level 100-200 mg imipramine equivalents showed an average improvement of 53% by 'intention-to- treat'. Higher doses were not accompanied by increased efficacy, while lower doses showed reduction in efficacy. Adverse events significantly increased with dose. CONCLUSIONS: With a low dose of antidepressants, clinicians trade off a slightly reduced chance of improvement for a higher chance of avoiding adverse reactions.

This article has been cited by other articles:

				I. Anderson, I. Ferrier, R. Baldwin, P. Cowen, L Howard, G Lewis, K Matthews, R. McAllister-Williams, R. Peveler, J Scott, et al. Evidence-based guidelines for treating depressive disorders with antidepressants: A revision of the 2000 British Association for Psychopharmacology guidelines J Psychopharmacol, June 1, 2008; 22(4): 343 - 396. [Abstract] [PDF]

				C. Barbui, A. Cipriani, and J. R Geddes Antidepressants and suicide symptoms: compelling new insights from the FDA's analysis of individual patient level data Evid. Based Ment. Health, May 1, 2008; 11(2): 34 - 35. [Full Text] [PDF]

				S. Heres, W. Kissling, and S. Leucht Review: little evidence to support dose escalation of selective serotonin reuptake inhibitors in non-responders Evid. Based Ment. Health, May 1, 2007; 10(2): 46 - 46. [Full Text] [PDF]

				J. Simon, S. Pilling, R. Burbeck, and D. Goldberg Treatment options in moderate and severe depression: decision analysis supporting a clinical guideline The British Journal of Psychiatry, December 1, 2006; 189(6): 494 - 501. [Abstract] [Full Text] [PDF]

				H. G. RUHE, J. HUYSER, J. A. SWINKELS, and A. H. SCHENE Dose escalation for insufficient response to standard-dose selective serotonin reuptake inhibitors in major depressive disorder: Systematic review The British Journal of Psychiatry, October 1, 2006; 189(4): 309 - 316. [Abstract] [Full Text] [PDF]

				F. E. Lotrich, R. R. Bies, G. S. Smith, and B. G. Pollock Relevance of assessing drug concentration exposure in pharmacogenetic and imaging studies. J Psychopharmacol, July 1, 2006; 20(4 Suppl): 33 - 40. [Abstract] [PDF]

				F. E. Lotrich and B. G. Pollock Aging and Clinical Pharmacology: Implications for Antidepressants J. Clin. Pharmacol., October 1, 2005; 45(10): 1106 - 1122. [Abstract] [Full Text] [PDF]

				L. J. Fochtmann and A. J. Gelenberg Guideline Watch: Practice Guideline for the Treatment of Patients With Major Depressive Disorder, 2nd Edition Focus, January 1, 2005; 3(1): 34 - 42. [Full Text] [PDF]

				S. Pampallona, P. Bollini, G. Tibaldi, B. Kupelnick, and C. Munizza Combined Pharmacotherapy and Psychological Treatment for Depression: A Systematic Review Arch Gen Psychiatry, July 1, 2004; 61(7): 714 - 719. [Abstract] [Full Text] [PDF]

				H. Ruhe Review: Low dose tricyclic antidepressants may be effective for adults with acute depressive disorder Evid. Based Ment. Health, May 1, 2003; 6(2): 46 - 46. [Full Text] [PDF]

				J. Weiss, S.-M. G. Dormann, M. Martin-Facklam, C. J. Kerpen, N. Ketabi-Kiyanvash, and W. E. Haefeli Inhibition of P-Glycoprotein by Newer Antidepressants J. Pharmacol. Exp. Ther., April 1, 2003; 305(1): 197 - 204. [Abstract] [Full Text]

				J. MONCRIEFF The antidepressant debate The British Journal of Psychiatry, March 1, 2002; 180(3): 193 - 194. [Full Text] [PDF]

				S. PAMPALLONA, P. BOLLINI, G. TIBALDI, B. KUPELNICK, and C. MUNIZZA Patient adherence in the treatment of depression The British Journal of Psychiatry, February 1, 2002; 180(2): 104 - 109. [Abstract] [Full Text] [PDF]

				C. BARBUI and M. HOTOPF Amitriptyline v. the rest: still the leading antidepressant after 40 years of randomised controlled trials The British Journal of Psychiatry, February 1, 2001; 178(2): 129 - 144. [Abstract] [Full Text] [PDF]

				G. M Goodwin Review: lower doses of antidepressant drugs are effective and have fewer adverse effects in depression Evid. Based Med., January 1, 2000; 5(1): 22 - 22. [Full Text] [PDF]

				M. Philipp, R. Kohnen, K.-O Hiller, K. Linde, and M. Berner Hypericum extract versus imipramine or placebo in patients with moderate depression: randomised multicentre study of treatment for eight weeks • Commentary: Has hypericum found its place in antidepressant treatment? BMJ, December 11, 1999; 319(7224): 1534 - 1539. [Abstract] [Full Text]

				G. M Goodwin Review: lower doses of antidepressant drugs are effective and have fewer adverse effects in depression Evid. Based Ment. Health, November 1, 1999; 2(4): 106 - 106. [Full Text]

				P. L Cornwall, J. Moncrieff, and U. F. Malt Naturalistic treatment study of depression in general practice BMJ, October 2, 1999; 319(7214): 921 - 921. [Full Text]

				S. Hollis and F. Campbell What is meant by intention to treat analysis? Survey of published randomised controlled trials BMJ, September 11, 1999; 319(7211): 670 - 674. [Abstract] [Full Text]

				S. Kisely Review: antidepressants improve depression in adults with physical illnesses Evid. Based Ment. Health, August 1, 1999; 2(3): 78 - 78. [Full Text]